Description
A selective estrogen receptor modulator, selectively binds to human ERα (IC50 = 1.5 nM); inhibits bone loss in ovariectomized rats; in clinical studies 0.5 mg/day associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke and increased risk of venous thromboembolic events; an inverse agonist at the CB2 cannabinoid receptor,
Formal name: (5R,6S)-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol
Synonyms: CP 336,156
Molecular weight: 413.6
CAS: 180916-16-9
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Inverse Agonists||Research Area|Endocrinology & Metabolism|Hormones & Receptors|Estrogens & Progestins||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors